Convergent Therapeutics, Inc. shared a post on LinkedIn:
“Convergent Therapeutics, Inc. CEO Philip Kantoff, joined the BioSpace Denatured podcast for an in-depth discussion on the evolving role of radiopharmaceuticals in oncology and the potential for alpha-based radioantibodies to address a significant unmet need in prostate cancer.
The conversation focused on patients with metastatic castration-resistant prostate cancer, particularly those who have been treated with some of the most advanced therapies currently available, including Lu-177-PSMA targeted approaches, and still require additional options.
Dr. Kantoff also discussed the initial data supporting Convergent’s development of CONV01-α, as well as the growing maturity of the Actinium-225 (Ac-225) supply chain to support late-stage clinical development and future commercialization of alpha-based therapies.
Thank you to Jennifer Smith-Parker for the thoughtful questions, and to fellow panelist Dr. Marc Hedrick for his valuable insights. ”
Other articles featuring Philip Kantof on OncoDaily.